Boston, MA -- (SBWIRE) -- 01/23/2015 -- A thriving pharmaceutical market, active improvements to regulatory practices, and the government 's commitment to healthcare services will continue to make Brazil a regional outperformer. A growing population and strategies for improved clinical research will ensure the development of the Brazilian market. Continued domestic competition and the need for further regulatory change will still pose challenges.

Headline Expenditure Projections

Pharmaceuticals: BRL57.0bn (USD26.4bn) in 2013 to BRL62.0bn (USD26.6bn) in 2014; +8.8% in local currency terms and +0.8% in US dollar terms. Forecast has been maintained from Q414.

Healthcare: BRL449.4bn (USD208.2bn) in 2013 to BRL492.46bn (USD211.4bn) in 2014; +9.6% in local currency terms and +1.5% in US dollar terms. Forecast has been revised upward from Q414 due to changes in historical data

View Full Report Details and Table of Contents

Risk/Reward Index: Brazil scores 60.3 in BMI's Pharmaceutical and Healthcare Risk/Reward Index (RRI), making it the fifth most attractive pharmaceutical market in the Americas. We highlight that Brazil will continue to be the most important market for multinationals in Latin America. Its position has been very well reflected by this quarter's RRR scores.

Key Trends And Developments

- In November 2014, the Deputy Director of the China FDA confirmed an agreement with Brazil's National Health Surveillance Agency (ANVISA) to enhance bilateral cooperation on good manufacturing practices (GMPs) for pharmaceutical drugs.
- In October 2014, ANVISA approved the interchangeability of similar drugs and branded medicines listed in the prescription.
- In October 2014, Hovione announced that Asian countries such as India and China are expected to lose their status as global hubs for producing active pharmaceutical ingredients (APIs) due to the rising cost of wages and changing regulatory environments in developed countries, reports In-Pharma. Brazil was named as one country that would be a part of the second wave of emerging regions in...

The Brazil Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Brazil Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Brazil pharmaceutical and healthcare industry.

Key Benefits

- Benchmark BMI's pharmaceutical and healthcare market forecasts for Brazil, to test other views - a key input for successful budgeting and strategic business planning in the Brazilian pharmaceutical and healthcare market.
- Target business opportunities and risks in the Brazilian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Brazil.
- Assess the activities, strategy and market position of your competitors via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI?s forecast analysis, and taken together with BMI?s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ?000 population).
Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
OTC Drug Market: OTC sales (USDbn & % of total sales).
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q1 2015
- Vietnam Pharmaceuticals & Healthcare Report Q1 2015
- United Arab Emirates Pharmaceuticals & Healthcare Report Q1 2015
- Malaysia Pharmaceuticals & Healthcare Report Q1 2015
- Peru Pharmaceuticals & Healthcare Report Q1 2015